Unknown PHASE2 INTERVENTIONAL 1-arm NCT04160416

mXELOXIRI Combined With Molecular Targeted Drug in mCRC (TRICAP)

mXELOXIRI Combined With Molecular Targeted Drug as First-line Therapy in Patients With Initially Unresectable Metastatic Colorectal Cancer: A Phase II, Single-arm, Prospective Clinical Study

Sponsor: First Affiliated Hospital of Zhejiang University

Conditions Unresectable Metastatic Colorectal Cancer

Interventions Capecitabine-Oxaliplatin-Irinotecan Combination

Updated 5 times since 2019 Last updated: Nov 17, 2019 Started: Jul 1, 2019 Primary completion: Nov 1, 2020 Completion: Jan 1, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Unresectable Metastatic Colorectal Cancer, this trial is ongoing. The trial is conducted by First Affiliated Hospital of Zhejiang University and has accumulated 5 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2022 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Jan 2021 — Jan 2022 [monthly]

Recruiting PHASE2
Dec 2019 — Jan 2021 [monthly]

Recruiting PHASE2

First recorded

Jul 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

First Affiliated Hospital of Zhejiang University

Data source: First Affiliated Hospital of Zhejiang University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hangzhou, China